Status:
RECRUITING
DAratumumab and REvlimid REfractory MM
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
Eligibility Criteria
Inclusion
- Phase I
- Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
- Patients aged ≥ 18 years
- Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
- Phase II
- Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
- Patients aged ≥ 18 years
- Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
Exclusion
- Patients not willing to consent to review of clinical data
Key Trial Info
Start Date :
August 21 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 21 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06541860
Start Date
August 21 2023
End Date
August 21 2028
Last Update
August 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Irccs San Matteo Pavia
Pavia, PV, Italy, 27100